Literature DB >> 8709122

The properties of known drugs. 1. Molecular frameworks.

G W Bemis1, M A Murcko.   

Abstract

In order to better understand the common features present in drug molecules, we use shape description methods to analyze a database of commercially available drugs and prepare a list of common drug shapes. A useful way of organizing this structural data is to group the atoms of each drug molecule into ring, linker, framework, and side chain atoms. On the basis of the two-dimensional molecular structures (without regard to atom type, hybridization, and bond order), there are 1179 different frameworks among the 5120 compounds analyzed. However, the shapes of half of the drugs in the database are described by the 32 most frequently occurring frameworks. This suggests that the diversity of shapes in the set of known drugs is extremely low. In our second method of analysis, in which atom type, hybridization, and bond order are considered, more diversity is seen; there are 2506 different frameworks among the 5120 compounds in the database, and the most frequently occurring 42 frameworks account for only one-fourth of the drugs. We discuss the possible interpretations of these findings and the way they may be used to guide future drug discovery research.

Mesh:

Substances:

Year:  1996        PMID: 8709122     DOI: 10.1021/jm9602928

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  350 in total

1.  A genetic algorithm for the automated generation of small organic molecules: drug design using an evolutionary algorithm.

Authors:  D Douguet; E Thoreau; G Grassy
Journal:  J Comput Aided Mol Des       Date:  2000-07       Impact factor: 3.686

Review 2.  An overview of the diversity represented in commercially-available databases.

Authors:  Mary P Bradley
Journal:  J Comput Aided Mol Des       Date:  2002 May-Jun       Impact factor: 3.686

3.  Synthesis and diversification of 1,2,3-triazole-fused 1,4-benzodiazepine scaffolds.

Authors:  James R Donald; Stephen F Martin
Journal:  Org Lett       Date:  2011-01-28       Impact factor: 6.005

4.  A reagent-based strategy for the design of large combinatorial libraries: a preliminary experimental validation.

Authors:  Gergely M Makara; Huw Nash; Zhongli Zheng; Jean-Paul A Orminati; Edward A Wintner
Journal:  Mol Divers       Date:  2003       Impact factor: 2.943

Review 5.  An overview of the diversity represented in commercially-available databases.

Authors:  Mary P Bradley
Journal:  Mol Divers       Date:  2002       Impact factor: 2.943

6.  Analysis of high-throughput screening assays using cluster enrichment.

Authors:  Minya Pu; Tomoko Hayashi; Howard Cottam; Joseph Mulvaney; Michelle Arkin; Maripat Corr; Dennis Carson; Karen Messer
Journal:  Stat Med       Date:  2012-07-05       Impact factor: 2.373

7.  Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles.

Authors:  Paul A Clemons; Nicole E Bodycombe; Hyman A Carrinski; J Anthony Wilson; Alykhan F Shamji; Bridget K Wagner; Angela N Koehler; Stuart L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

8.  The Development of Target-Specific Pose Filter Ensembles To Boost Ligand Enrichment for Structure-Based Virtual Screening.

Authors:  Jie Xia; Jui-Hua Hsieh; Huabin Hu; Song Wu; Xiang Simon Wang
Journal:  J Chem Inf Model       Date:  2017-06-01       Impact factor: 4.956

9.  Expansion of the structure-activity relationships of BACE1 inhibitors by harnessing diverse building blocks prepared using a unified synthetic approach.

Authors:  Joan Mayol-Llinàs; Shiao Chow; Adam Nelson
Journal:  Medchemcomm       Date:  2019-03-22       Impact factor: 3.597

10.  Benchmarking methods and data sets for ligand enrichment assessment in virtual screening.

Authors:  Jie Xia; Ermias Lemma Tilahun; Terry-Elinor Reid; Liangren Zhang; Xiang Simon Wang
Journal:  Methods       Date:  2014-12-03       Impact factor: 3.608

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.